WO2016143816A1 - Gpc3由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 - Google Patents
Gpc3由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 Download PDFInfo
- Publication number
- WO2016143816A1 WO2016143816A1 PCT/JP2016/057356 JP2016057356W WO2016143816A1 WO 2016143816 A1 WO2016143816 A1 WO 2016143816A1 JP 2016057356 W JP2016057356 W JP 2016057356W WO 2016143816 A1 WO2016143816 A1 WO 2016143816A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- amino acid
- hla
- cells
- antigen
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 139
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims description 51
- 206010028980 Neoplasm Diseases 0.000 title claims description 41
- 201000011510 cancer Diseases 0.000 title claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 32
- 230000036039 immunity Effects 0.000 title claims description 24
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 230000002265 prevention Effects 0.000 title description 6
- 239000000411 inducer Substances 0.000 title description 4
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 21
- 230000001939 inductive effect Effects 0.000 claims description 34
- 229940024606 amino acid Drugs 0.000 claims description 24
- 150000001413 amino acids Chemical group 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 229960005486 vaccine Drugs 0.000 claims description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 229930182817 methionine Chemical group 0.000 claims description 7
- 239000004474 valine Chemical group 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 230000005847 immunogenicity Effects 0.000 claims description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 23
- 210000004027 cell Anatomy 0.000 description 50
- 102000011786 HLA-A Antigens Human genes 0.000 description 36
- 108010075704 HLA-A Antigens Proteins 0.000 description 36
- 210000004443 dendritic cell Anatomy 0.000 description 32
- 238000000034 method Methods 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 102000010956 Glypican Human genes 0.000 description 19
- 108050001154 Glypican Proteins 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 17
- 108091033319 polynucleotide Proteins 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- 108050007237 Glypican-3 Proteins 0.000 description 14
- 238000002659 cell therapy Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 10
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 10
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 9
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 9
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 229940079322 interferon Drugs 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000012286 ELISA Assay Methods 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000001638 lipofection Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 238000011510 Elispot assay Methods 0.000 description 5
- 239000007376 cm-medium Substances 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000002998 immunogenetic effect Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000001808 exosome Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000003799 water insoluble solvent Substances 0.000 description 2
- 239000003021 water soluble solvent Substances 0.000 description 2
- KQMBIBBJWXGSEI-ROLXFIACSA-N (2s)-2-amino-3-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CNC=N1 KQMBIBBJWXGSEI-ROLXFIACSA-N 0.000 description 1
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 description 1
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- -1 Fmoc amino acids Chemical class 0.000 description 1
- 102300055439 Glypican-3 isoform 2 Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101150118346 HLA-A gene Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 108010007811 human immunodeficiency virus p17 gag peptide Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Definitions
- the present invention relates to a peptide derived from GPC3, more specifically, an immunogenic peptide that presents an antigen to T cells through binding to a human leukocyte antigen, and a pharmaceutical composition for treating or preventing cancer using the same Product, immunity-inducing agent, and method for producing antigen-presenting cells.
- cancer cells In vivo, it is thought that cancer cells always occur accidentally, but usually a specific cancer antigen-exclusion reaction due to innate immunity occurs, and then a specific immune response is induced and lymphatic It is assumed that cancer cells are eliminated by spheres.
- HLA human leukocyte antigen
- lymphocytes In order for cancer cell-derived antigens to be recognized, human leukocyte antigen (HLA) present on the cell surface and lymphocytes must form a complex. HLA molecules that are major histocompatibility antigens are roughly classified into class I molecules (HLA-A type, B type, C type) and class II molecules (HLA-DP type, DQ type, DR type).
- CTLs cytotoxic T cells
- CTL epitopes cancer antigens consisting of 8 to 11 amino acids presented on HLA class I molecules on the surface of cancer cells receive T cell antigens on CTLs. It is induced by being specifically recognized by the body (TCR).
- JP-A-8-151396 discloses an oligopeptide comprising a specific amino acid sequence. Is described as having HLA binding properties.
- HLA binding properties Many peptides having HLA binding properties are known, but there is a further demand for peptides that can be used for the treatment or prevention of various cancers. Moreover, since HLA is a gene rich in polymorphism, there is also a demand for a multitype immunogenic peptide corresponding to a plurality of HLA types.
- the present invention has been made in view of the above circumstances, and is an immunogenic peptide that binds to an HLA class I molecule, particularly a peptide capable of inducing CTL, and a pharmaceutical composition for treating or preventing cancer using the same.
- An object of the present invention is to provide an immune inducer, a method for producing antigen-presenting cells, and the like.
- the present invention includes the following inventions.
- a peptide comprising 8 or more consecutive amino acid residues in the amino acid sequence represented by any of SEQ ID NOs: 1 to 11 and consisting of 11 or less amino acid residues.
- the peptide according to (1) wherein one or several amino acids are substituted, inserted, deleted or added in the amino acid sequence and have immunogenicity.
- the second amino acid is substituted with tyrosine, phenylalanine, methionine, tryptophan, valine, leucine or glutamine, and / or the C-terminal amino acid is substituted with phenylalanine, leucine, isoleucine, tryptophan, methionine or valine.
- a pharmaceutical composition for treating or preventing cancer comprising the peptide according to any one of (1) to (3).
- the pharmaceutical composition according to (4) which is in the form of a vaccine.
- An immunity-inducing agent comprising the peptide according to any one of (1) to (3).
- the immunity-inducing agent according to (7) which induces cytotoxic T cells.
- a method for producing an antigen-presenting cell having CTL-inducing activity comprising a step of contacting the peptide according to any one of (1) to (3) and an antigen-presenting cell in vitro.
- the peptide of the present invention has a high HLA binding property and a high CTL inducing ability, it is highly expected to be useful as a cancer vaccine.
- Application to various immunotherapy, especially dendritic cell therapy is also envisaged.
- Glypican-3 is a protein belonging to the Glypican family.
- Glypican is a kind of proteinglycan and is known to bind to glycosyl-phosphatidylinositol on the cell surface.
- Glypican regulates the activity of various cell growth factors including Wnts, but this action is thought to be because Glypican promotes or inhibits the interaction between these cell growth factors and their receptors. Yes.
- GPC3 is expressed in almost all hepatocellular carcinoma (HCC), while being hardly expressed in normal liver and cirrhosis.
- GPC3 is known to be highly expressed not only in hepatocellular carcinoma but also in melanoma and ovarian cancer. 1.
- Glypican-3 a marker and a therapeutic target in hepatocellular carcinoma. Jorge Filmus and Mariana Capurro, FEBS J., 280: 2471-2476, 2013. 2. "Glypican-3: a new target for cancer immunotherapy.” Mitchell Ho and Heungnam Kim, Eur. J. Cancer, 47, 333-338, 2011.
- a plurality of peptides that are GPC3-derived peptides different from those reported in the above clinical studies and that bind to HLA molecules and have immunity-inducing ability were identified.
- a specific peptide of the present invention can bind to a plurality of HLA types. Therefore, according to the peptide of the present invention, it is possible to provide a cancer vaccine, a dendritic cell therapy, etc. that cover a very wide range of cancer patients.
- FIG. 1 shows the result of an ELISPOT assay (IFN ⁇ ) when a sample from a patient [0] (HLA type: 24: 02/24: 02) receiving dendritic cell therapy for HSP70 was stimulated with the peptide of SEQ ID NO: 1. number of ⁇ -producing cells).
- FIG. 2 shows the results of an ELISPOT assay (IFN) when samples from patients receiving dendritic cell therapy for HSP70 (HLA type: 02: 01/24: 02) were stimulated with the peptide of SEQ ID NO: 1, 2 or 4. -Number of ⁇ -producing cells).
- IFN ⁇ ELISPOT assay
- FIG. 3 shows the results of an ELISPOT assay (IFN) when samples from patients receiving dendritic cell therapy for HSP70 (HLA type: 02: 01/33: 03) were stimulated with the peptide of SEQ ID NO: 1, 2, or 4. -Number of ⁇ -producing cells).
- FIG. 4 shows the results of an ELISA assay (IFN) when a sample from a patient receiving dendritic cell therapy for HSP70 (HLA type: 24: 02/26: 01) was stimulated with the peptide of SEQ ID NO: 1, 2, or 4. -Number of ⁇ -producing cells).
- IFN ELISPOT assay
- FIG. 5 shows the results of an ELISA assay (IFN) when samples from patients receiving dendritic cell therapy for HSP70 (HLA type: 24: 02/24: 02) were stimulated with the peptide of SEQ ID NO: 1, 2 or 4. -Number of ⁇ -producing cells).
- FIG. 6 shows the results of an ELISA assay (IFN) when samples from patients receiving dendritic cell therapy for HSP70 (HLA type 11: 01/24: 02) were stimulated with the peptide of SEQ ID NO: 1, 2 or 4. -Number of ⁇ -producing cells).
- IFN ELISA assay
- FIG. 7 shows the results of an ELISA assay (IFN) when samples from patients receiving dendritic cell therapy for HSP70 (HLA type: 02: 01/24: 02) were stimulated with the peptide of SEQ ID NO: 1, 2 or 4 -Number of ⁇ -producing cells).
- FIG. 8 shows the results of an ELISA assay (IFN) when a sample from a patient who received dendritic cell therapy for HSP70 (HLA type: 02: 01/33: 03) was stimulated with the peptide of SEQ ID NO: 1, 2 or 4. -Number of ⁇ -producing cells).
- the peptide according to the present invention comprises 8 or more consecutive amino acid residues in the amino acid sequence represented by any of SEQ ID NOs: 1 to 11, and a total of 11 or less, preferably 10 or less, more preferably 9 It is a peptide consisting of the following amino acid residues.
- the peptide of the present invention may consist of the amino acid sequence represented by any of SEQ ID NOs: 1 to 11.
- the peptide of the present invention is derived from GPC3 which is one of Glypican. Based on the amino acid sequence that constitutes GPC3, the binding with the HLA molecule predicted by a hypothesis obtained by using the active learning experiment method (Japanese Patent Laid-Open No. 8-151396) is 3 or more in terms of -log Kd value. The amino acid sequence was selected.
- amino acid sequences constituting the peptides of the present invention and their HLA binding prediction scores are shown in Table 1 below.
- the peptide of the present invention has an HLA-binding property and is immunogenic (hereinafter sometimes simply referred to as “HLA peptide” or “immunogenic peptide”).
- immunogenic means that an immune response can be induced, for example, having CTL inducing activity and thus having cytotoxic activity against cancer cells. To do.
- the peptide of the present invention is a multi-HLA peptide capable of binding to a plurality of allelic forms of HLA-A gene A.
- the peptide of SEQ ID NO: 7 comprises the product of the HLA-A * 24: 02 gene (HLA-A * 24: 02 molecule), the product of the HLA-A * 0201 gene (HLA-A * 02: 01 molecule) and the HLA -A * 02: 06 gene product (HLA-A * 02: 06 molecule) binds strongly and has high immunogenicity.
- the HLA subtype to which the peptide of the present invention can bind is not limited to HLA-A * 24: 02, HLA-A * 02: 01, and HLA-A * 02: 06.
- these HLA subtypes cover about 85% of Orientals including Japanese and about 55% of Westerners, the multi-HLA peptide of the present invention has a wide patient coverage in immunotherapy and the like. It is thought to have.
- the amino acid residues constituting the amino acid sequences of SEQ ID NOs: 1 to 11 or a part thereof may be modified.
- the amino acid sequences represented by SEQ ID NOs: 1 to 11 are intended to be presented on antigen-presenting cells, but when the peptide of the present invention is directly administered into the body, depending on the administration route, the end of the peptide may be digested in the digestive tract or the like. May undergo changes such as being digested. Therefore, the peptide of the present invention is incorporated into the antigen-presenting cell so that the amino acid residues represented by SEQ ID NOs: 1 to 11 are retained when binding to a predetermined HLA class I molecule on the antigen-presenting cell. May exist in the form of a precursor having one or more amino acid residues added to the N-terminal and / or C-terminal.
- amino acid is used in its broadest sense, and includes artificial amino acid variants and derivatives in addition to natural amino acids.
- amino acids include natural proteinaceous L-amino acids; D-amino acids; chemically modified amino acids such as amino acid variants and derivatives; natural non-protein amino acids such as norleucine, ⁇ -alanine, ornithine; and amino acid characteristics.
- unnatural amino acids include ⁇ -methyl amino acids (such as ⁇ -methylalanine), D-amino acids, histidine-like amino acids (such as ⁇ -hydroxy-histidine, homohistidine, ⁇ -fluoromethyl-histidine and ⁇ -methyl-histidine) Amino acids having an extra methylene in the side chain (“homo" amino acids) and amino acids in which the carboxylic acid functional amino acids in the side chain are replaced with sulfonic acid groups (such as cysteic acid).
- ⁇ -methyl amino acids such as ⁇ -methylalanine
- D-amino acids such as ⁇ -methylalanine
- histidine-like amino acids such as ⁇ -hydroxy-histidine, homohistidine, ⁇ -fluoromethyl-histidine and ⁇ -methyl-histidine
- Amino acids having an extra methylene in the side chain (“homo" amino acids)
- the second amino acid constituting the peptide may be substituted with tyrosine, phenylalanine, methionine, or tryptophan and / or the C-terminus. These amino acids may be substituted with phenylalanine, leucine, isoleucine, tryptophan or methionine.
- the second amino acid may be substituted with leucine or methionine, and / or the C-terminal amino acid may be substituted with valine or leucine. Good.
- the amino acid at the second position may be substituted with valine or glutamine, and / or the C-terminal amino acid may be substituted with valine or leucine. Good.
- any of the peptides of the present invention can be produced using techniques known to those skilled in the art. For example, you may synthesize
- a desired peptide may be produced by expressing a polynucleotide encoding the peptide of the present invention or a recombinant vector containing the polynucleotide.
- any of the peptides thus obtained can be identified using techniques known to those skilled in the art. For example, identification can be performed using Edman decomposition or mass spectrometry.
- compositions for treating or preventing cancer according to the present invention comprises, as an active ingredient, for example, eight or more consecutive amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 11
- a peptide comprising amino acid residues and a total of 11 or less, preferably 10 or less, more preferably 9 or less amino acid residues is included.
- the peptide contained in the pharmaceutical composition may consist of the amino acid sequence represented by any of SEQ ID NOs: 1-11. The peptide is as defined above.
- the active ingredient of the pharmaceutical composition of the present invention is not limited to the peptide of the present invention, but can be a component capable of directly or indirectly inducing CTL, for example, a polynucleotide encoding the peptide or a vector containing the same, or the same It may be an antigen-presenting cell that presents a complex of a peptide and an HLA molecule on the surface, an exosome secreted from the antigen-presenting cell, or a combination thereof.
- antigen-presenting cells to be used examples include macrophages and dendritic cells, but it is preferable to use dendritic cells with high CTL inducing ability.
- Other ingredients known to be used in cancer treatment such as chemokines, cytokines, tumor necrosis factors, chemotherapeutic agents, etc. may be included in the pharmaceutical composition of the present invention.
- the dose of peptide may be, for example, about 1-10 mg per day when the patient is an adult. However, since the dose varies depending on the age, weight, administration method, etc. of the patient, it is appropriately determined by those skilled in the art.
- the pharmaceutical composition of the present invention is useful for killing cancer cells and the like by the following mechanism of action.
- the pharmaceutical composition of the present invention is administered to a specific cancer patient, the peptide in the pharmaceutical composition is presented in the state of being bound to the HLA molecule on the surface of the antigen-presenting cell.
- CTL recognizes a peptide on such an antigen-presenting cell, it is activated and proliferates to the systemic circulation.
- a peptide-specific CTL enters cancer tissue, it recognizes the same peptide derived from a specific cancer antigen that is naturally bound to the HLA molecule on the surface of the cancer cell, and kills the cancer cell. This function can contribute to the treatment of cancer.
- the pharmaceutical composition of the present invention can be used for the prevention of cancer.
- the pharmaceutical composition of the present invention when the pharmaceutical composition of the present invention is administered to a healthy human body, CTL is induced, and the induced cytotoxic T cells remain in the body. Can be injured. Similarly, recurrence of cancer may be prevented by administering to the human body after cancer treatment.
- any cancer that expresses GPC3 is envisaged as a cancer to be treated or prevented.
- hepatocellular carcinoma skin cancer such as melanoma, ovarian cancer and the like can be mentioned.
- the peptide of the present invention is considered to be particularly effective for the treatment or prevention of hepatocellular carcinoma.
- active ingredients such as immunogenic peptides can be contained in the pharmaceutical composition of the present invention.
- the pharmaceutical composition of the present invention can be dissolved in a water-soluble solvent, formulated as a pharmaceutically acceptable salt, and administered to a patient.
- a water-soluble solvent formulated as a pharmaceutically acceptable salt
- Such pharmaceutically acceptable salt forms include physiologically acceptable water-soluble salts, such as sodium, potassium, magnesium, calcium, and the like, buffered at physiological pH. Can be mentioned.
- a water-insoluble solvent can also be used. Examples of such a water-insoluble solvent include alcohols such as ethanol and propylene glycol.
- the preparation containing the pharmaceutical composition of the present embodiment may contain drugs for various purposes.
- drugs include preservatives and buffering agents.
- Preservatives include sodium bisulfite, sodium bisulfate, sodium thiosulfate benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, methylparaben, polyvinyl alcohol, phenylethyl alcohol, ammonia, dithiothreitol, beta
- Examples of the buffer include sodium carbonate, sodium borate, sodium phosphate, sodium acetate, sodium bicarbonate and the like. These agents can be present in an amount that can maintain the pH of the system between 2 and 9, preferably between 4 and 8.
- the dosage form of the pharmaceutical composition of the present invention is not particularly limited, but when used as a vaccine form, the dosage form is exemplified by injection (muscular, subcutaneous, intradermal), oral preparation, nasal preparation and the like.
- the pharmaceutical composition of the present invention may be a mixed cocktail vaccine containing a plurality of types of active ingredients.
- such a vaccine may contain a plurality of active ingredients in combination with any two or more of the peptides represented by SEQ ID NOs: 1 to 11, or other active ingredients.
- the vaccine of the present invention is a component other than the pharmaceutical composition, and is an inactive component-containing vaccine that contains a component that is not active in itself and has the effect of further enhancing the effect of the pharmaceutical composition as a vaccine.
- inactive ingredients include adjuvants and toxoids.
- adjuvants include, but are not intended to be limited, those of sedimentary type such as aluminum hydroxide, aluminum phosphate, calcium phosphate, and oily types such as Freund's complete adjuvant and Freund's incomplete adjuvant. It is done.
- the pharmaceutical composition of the present invention is preferably injected or infused by intradermal, subcutaneous, intravenous, intramuscular administration or the like, or transdermally or inhaled from mucous membranes such as nasal and pharynx, etc.
- the single dose can be set between an amount that can significantly induce cytotoxic T cells and an amount that does not significantly damage non-cancer cells.
- the pharmaceutical composition of the present invention is intended not only for administration to the human body but also for use outside the body. More specifically, the pharmaceutical composition of the present invention may be used to stimulate CTL inducing activity by stimulating antigen-presenting cells in vitro or ex vivo.
- the pharmaceutical composition of the present invention when used for cancer dendritic cell therapy as an example, is preliminarily contacted with antigen-presenting cells such as dendritic cells derived from patients in need of cancer treatment or prevention. Then, the antigen-presenting cells can be administered to the patient by returning them to the patient.
- the peptide contained in the pharmaceutical composition can be introduced into the antigen-presenting cell by, for example, the lipofection method or the injection method.
- the polynucleotide can be introduced into an antigen-presenting cell by a technique known in the art.
- a patient-derived antigen-presenting cell is transformed in vitro with a target polynucleotide or a vector encoding the polynucleotide by lipofection, electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate, etc. It may be converted.
- the immune inducer according to the present invention contains, as an active ingredient, for example, eight or more consecutive amino acid residues in one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 11, and 11 Hereinafter, it includes peptides consisting of amino acid residues, preferably 10 or less, more preferably 9 or less.
- the peptide contained in the immunity-inducing agent may consist of the amino acid sequence represented by any of SEQ ID NOs: 1-11. The peptide is as defined above.
- the active ingredient of the immunity-inducing agent of the present invention is not limited to the peptide of the present invention, but a component capable of directly or indirectly inducing immunity, for example, a polynucleotide encoding the peptide of the present invention or an expression vector comprising the same Alternatively, it may be an antigen-presenting cell that presents a complex of the peptide and HLA molecule on the surface, an exosome secreted from the antigen-presenting cell, or a combination thereof.
- antigen-presenting cells to be used include macrophages and dendritic cells, but it is preferable to use dendritic cells with high CTL inducing ability.
- the immunity-inducing agent of the present invention is intended not only for administration to the human body but also for use outside the body. More specifically, the immunity-inducing agent of the present invention may be used for stimulating antigen-presenting cells in vitro or ex vivo to increase CTL-inducing activity.
- the immunity-inducing agent of the present invention is pre-contacted with antigen-presenting cells such as dendritic cells derived from a patient in need of immunity induction, This antigen-presenting cell can be administered to the patient by returning it to the patient.
- the peptide contained in the immunity-inducing agent can be introduced into antigen-presenting cells by, for example, transfection via a liposome (lipofection method), injection method or the like.
- a polynucleotide encoding the peptide of the present invention is used in such an application, the polynucleotide can be introduced into an antigen-presenting cell by a technique known in the art.
- a patient-derived antigen-presenting cell can be transformed in vitro with a target polynucleotide or a vector expressing the polynucleotide by lipofection, electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate, etc. It may be converted.
- immune induction means to induce an immune response, for example, to increase the CTL-inducing activity of antigen-presenting cells and further to increase the cytotoxic activity of CTLs against cancer cells.
- CTL induction refers to CTL that specifically recognizes an antigen in vitro or in vivo when the peptide of the present invention is presented on the surface of an antigen-presenting cell. Means to induce or proliferate, to differentiate naive T cells into effector cells with the ability to kill target cells such as cancer cells (cytotoxic activity) and / or to increase the cytotoxic activity of CTLs .
- the CTL inducing activity can be measured by evaluating the production of cytokine (eg, interferon (IFN) - ⁇ ) by CTL.
- cytokine eg, interferon (IFN) - ⁇
- the increase in cytokine-producing cells induced from progenitor cells by antigen-presenting cells such as peripheral blood mononuclear cells stimulated with the peptide of the present invention is measured by ELISA (Enzyme-Linked ImmunoSorbent Assay) or ELISA (Enzyme-Linked ImmunoSorbent Assay).
- CTL-inducing activity may be measured by evaluation using a known high-sensitivity immunoassay such as a method.
- the cytotoxic activity can also be measured by a known method such as a 51 Cr release method.
- Method for producing antigen-presenting cell comprises, for example, 8 or more consecutive amino acid residues in one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 11, And a step of contacting a peptide consisting of 11 or less, preferably 10 or less, more preferably 9 or less amino acid residues with antigen-presenting cells in vitro.
- the peptide used in the production method of the present invention may consist of the amino acid sequence represented by any of SEQ ID NOs: 1 to 11. The peptide is as defined above.
- the peptide used in the production method of the present invention is considered to bind to an HLA class I molecule on the surface of an antigen-presenting cell and is presented to the CTL as an antigen peptide, thereby inducing CTL activity of the antigen-presenting cell. Therefore, the contact with the antigen-presenting cell is not limited to the peptide of the present invention, and a component capable of directly or indirectly inducing CTL, for example, a polynucleotide encoding the peptide, a vector containing the same, or the peptide It may be an antigen-presenting cell that presents a complex with an HLA molecule on the surface, an exosome secreted from the antigen-presenting cell, or a combination thereof. Examples of antigen-presenting cells to be used include macrophages and dendritic cells, but it is preferable to use dendritic cells with high CTL inducing ability.
- the antigen-presenting cells produced by the production method of the present invention are intended not only to be used as an active ingredient of the above pharmaceutical composition or immunity-inducing agent, but also to be used for immunotherapy and the like.
- the antigen-presenting cells to be produced are antigen-presenting cells such as dendritic cells with low CTL-inducing ability derived from patients who require immunity induction. After being previously contacted, the antigen-presenting cells can be administered to the patient by returning them to the patient.
- the peptide of the present invention can be introduced into antigen-presenting cells by, for example, transfection via a liposome (lipofection method), injection method or the like.
- the polynucleotide can be introduced into an antigen-presenting cell by a technique known in the art.
- a patient-derived antigen-presenting cell is transformed in vitro with a target polynucleotide or a vector encoding the polynucleotide by lipofection, electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate, etc. It may be converted.
- the prediction / experiment / evaluation procedure in this example was performed based on the active learning experiment plan described in the pamphlet of International Publication No. 2006/004182, and rules were constructed by repeating the following steps as a whole.
- the peptide at the selected question point is manufactured by the synthesis / purification method described later, and the actual binding ability is measured by an experiment described later and added to the accumulated data.
- amino acid sequences shown in SEQ ID Nos: 1 to 11 were extracted according to the rules described above.
- Peptides having the amino acid sequences of SEQ ID NOs: 1 to 11 were manually synthesized by the Merrifield solid phase method using Fmoc amino acids. After deprotection, reverse phase HPLC purification was performed using a C18 column to a purity of 95% or higher. Peptide identification and purity were confirmed by MALDI-TOF mass spectrometry (AB SCIEX MALDI-TOF / TOF5800). Peptide quantification was performed by Micro BCA assay (Thermo Scientific) using BSA as a standard protein.
- C1R-A24 cells are exposed to acidic conditions of pH 3.3 for 30 seconds, and are associated with endogenous peptides that are originally bound to HLA-A * 24: 02 molecules and HLA class I molecules in common.
- the light chain ⁇ 2m was dissociated and removed.
- purified ⁇ 2m was added to C1R-A24 cells, added to a dilution series of peptides, and incubated on ice for 4 hours. During this period, staining was performed using a fluorescent-labeled monoclonal antibody 17A12 that recognizes a three-membered aggregate (MHC-pep) of HLA-A * 24: 02 molecule, peptide, and ⁇ 2m that reassociates.
- MHC-pep three-membered aggregate
- the number of MHC-pep per C1R-A24 cell was quantitatively measured using a fluorescence cell analyzer FACScan (Becton-Dickinson). Based on the average fluorescence intensity per cell, the binding between HLA-A * 24: 02 molecule and peptide was performed by the method of the present inventor published in a paper (Udakaket al., Immunogenetics, 51, 816-828, 2000). The dissociation constant Kd value was calculated.
- T2 cells and purified ⁇ 2m were added to the serial dilution series of the peptide whose binding ability was to be measured, and then incubated at 37 ° C. for 4 hours.
- the HLA-A * 02: 01 molecule whose expression level increased depending on the concentration of the peptide was stained with an association-type specific fluorescent labeled monoclonal antibody BB7.2.
- RA2.6 cells were cultured overnight at 26 ° C., and a dilution series of peptides was added to the place where HLA-A * 02: 06 molecules not bound to the peptide were accumulated on the cell surface, and bound at 26 ° C. for 60 minutes. It was.
- amino acid sequences of SEQ ID NOs: 1 to 11 are the full-length sequence of a predetermined genomic protein of GPC3 registered in GENBANK (SEQ ID NO: 12) (> gi
- ⁇ Peptide immunity induction test (1) Preparation of peptide-stimulated dendritic cells Day 0 to 9 (induction of dendritic cells) Of the peripheral blood monocytes obtained by pheresis from the patient [0] who received dendritic cell therapy for HSP70, the cell fraction adhered to the culture flask was treated in AIM-CM medium (Gibco) for 10 days, 37 days. Incubated at 0 ° C. During the culture period, 15 ⁇ l of IL-4 and 30 ⁇ l of granulocyte monocyte colony stimulating factor (GM-CSF) were added to the medium on the 0th and 3rd days, respectively, and 15 ⁇ l of IL-4 and GM were added on the 5th day. -30 ⁇ l of CSF and 75 ⁇ l of tumor necrosis factor (TNF) - ⁇ were added.
- AIM-CM medium Gibco
- GM-CSF granulocyte monocyte colony stimulating factor
- the induced dendritic cells were newly collected in the AIM-CM medium, and the peptides of the present invention (SEQ ID NOs: 1 to 11) were added to 20 ⁇ g / ml. Thereafter, the medium containing dendritic cells was cultured at 37 ° C. for 2 hours. The following peptides were used as positive and negative controls.
- HLA-A * 24 Positive control for HLA-A * 24: 02 (EBV LMP2, 419-427: TYGPVFMCL (SEQ ID NO: 13)) Negative control for HLA-A * 24: 02 (HIV env gp160, 584-592: RYLRDQQLL (SEQ ID NO: 14)) Positive control for HLA-A * 02: 01 (Flu A MP, 58-66: GILGFVFTL (SEQ ID NO: 15)) Negative control for HLA-A * 02: 01 (HIV gap p17, 77-85: SLYNTVATL (SEQ ID NO: 16)) Positive control for HLA-A * 02: 06 (EBV LMP2 453-461: LTAGFLIFL (SEQ ID NO: 17)) Negative control for HLA-A * 02: 06 (HIV gap p24 341-349: ATLEEMMTA (SEQ ID NO: 18))
- Dendritic cells were collected, washed 3 times or more with a sufficient amount of AIM-CM medium, and then counted.
- CD8 T cells were separated from the medium and counted.
- ELISPOT assay Day 17 The CD8T cells were added to a 96 well plate for ELISPOT (manufactured by Millipore) coated with an anti-TFN- ⁇ monoclonal antibody (manufactured by MABTECH) at 2 ⁇ 10 4 cells / well. Three or more wells were used for each sample. 100 ⁇ l of AIM-V (Gibco) was added to each well. The 96-well plate for ELISPOT was cultured at 37 ° C.
- FIG. 1 shows the patient for HLA type 24: 02/24: 02
- FIG. 2 shows the patient for 02: 01/24: 02
- 02: The one for the 01/33: 03 patient is shown in FIG. In each figure, the average value of the assay results of three times is displayed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
(1)配列番号1~11のいずれかで表されるアミノ酸配列における連続した8以上のアミノ酸残基を含み、且つ11以下のアミノ酸残基から成るペプチド。
(2)前記アミノ酸配列中、1又は数個のアミノ酸が置換、挿入、欠失又は付加しており、且つ免疫原性を有する、(1)に記載のペプチド。
(3)前記アミノ酸配列中、第2位のアミノ酸がチロシン、フェニルアラニン、メチオニン、トリプトファン、バリン、ロイシン又はグルタミンで、そして/あるいはC末端のアミノ酸がフェニルアラニン、ロイシン、イソロイシン、トリプトファン、メチオニン又はバリンで置換されている、(2)に記載のペプチド。
(4)(1)~(3)のいずれかに記載のペプチドを含む、癌の治療又は予防のための医薬組成物。
(5)ワクチンの形態である、(4)に記載の医薬組成物。
(6)前記ペプチドが1又は複数の型のHLA分子と結合することができる、(4)又は(5)に記載の医薬組成物。
(7)(1)~(3)のいずれかに記載のペプチドを含む免疫誘導剤。
(8)細胞傷害性T細胞を誘導するための、(7)に記載の免疫誘導剤。
(9)前記ペプチドが1又は複数の型のHLA分子と結合することができる、(7)又は(8)に記載の免疫誘導剤。
(10)(1)~(3)のいずれかに記載のペプチドと抗原提示細胞とをin vitroで接触させる工程を含む、CTL誘導活性を有する抗原提示細胞の製造方法。
1."Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma." Jorge Filmus and Mariana Capurro, FEBS J., 280: 2471-2476, 2013.
2."Glypican-3: a new target for cancer immunotherapy." Mitchell Ho and Heungnam Kim, Eur. J. Cancer, 47, 333-338, 2011.
3."Peptide vaccines for hepatocellular carcinoma." Daisuke Nobuoka, Toshiaki Yoshikawa, Yu Sawada, Toshiyoshi Fujiwara and Tetsuya Nakatsura, Human Vaccines & Immunotherapeutics, 9, 210-212, 2013.
4. "Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential fo Improving Overall Survival." Yu Sawada, et.al., Clin. Cancer. Res., 18, 3636-3696, 2012.
本発明に係るペプチドは配列番号1~11のいずれかで表されるアミノ酸配列における連続した8以上のアミノ酸残基を含み、且つ合計11以下、好ましくは10以下、より好ましくは9以下のアミノ酸残基から成るペプチドである。本発明のペプチドは配列番号1~11のいずれかで表されるアミノ酸配列から成るものであってもよい。本発明のペプチドはGlypicanの一つであるGPC3に由来する。GPC3を構成するアミノ酸配列に基づき、能動学習実験法(特開平8-151396号)を用いて得られる仮説により予測された、HLA分子との結合性が-logKd値に換算して3以上であるアミノ酸配列が選択された。
本発明に係る癌の治療又は予防のための医薬組成物は、有効成分として、例えば、配列番号1~11から成る群から選択される1種以上のアミノ酸配列における連続した8以上のアミノ酸残基を含み、且つ、合計11以下、好ましくは10以下、より好ましくは9以下のアミノ酸残基からなるペプチドを含む。医薬組成物に含まれるペプチドは配列番号1~11のいずれかで表されるアミノ酸配列から成るものであってもよい。当該ペプチドは上文で定義したとおりである。
本発明に係る免疫誘導剤は、有効成分として、例えば、配列番号1~11から成る群から選択される1種以上のアミノ酸配列における連続した8以上のアミノ酸残基を含み、且つ11以下、好ましくは10以下、より好ましくは9以下のアミノ酸残基からなるペプチドを含む。免疫誘導剤に含まれるペプチドは配列番号1~11のいずれかで表されるアミノ酸配列から成るものであってもよい。当該ペプチドは上文で定義したとおりである。
本発明に係る抗原提示細胞の製造方法は、例えば、配列番号1~11から成る群から選択される1種以上のアミノ酸配列における連続した8以上のアミノ酸残基を含み、且つ合計11以下、好ましくは10以下、より好ましくは9以下のアミノ酸残基からなるペプチドと抗原提示細胞とをin vitroで接触させる工程を含む。本発明の製造方法で使用されるペプチドは配列番号1~11のいずれかで表されるアミノ酸配列から成るものであってもよい。当該ペプチドは上文で定義したとおりである。
配列番号1~11のアミノ酸配列を有するペプチドは、Fmocアミノ酸を用い、Merrifieldの固相法にて、マニュアル合成をした。脱保護の後、C18カラムを用いて逆相HPLC精製をし、95%以上の純度にした。ペプチドの同定と純度の確認は、MALDI-TOF質量分析にて行った(AB SCIEX MALDI-TOF/TOF5800)。ペプチドの定量は、BSAを標準蛋白質としてMicro BCAアッセイ(Thermo Scientific社)にて行った。
HLA-A*24:02遺伝子の産物であるHLA-A*24:02分子へのペプチドの結合能の測定は、HLA-A*24:02分子を発現するC1R-A24細胞(熊本大学、滝口雅文教授作成のものを、許可を得て愛媛大学、安川正貴助教授から供与いただいた。)を用いて行った。
HLA-A*02:01遺伝子の産物であるHLA-A*02:01分子へのペプチドの結合能の測定は、HLA-A*02:01分子を発現する細胞株T2(ATCCより購入)を用いて行った。
HLA-A*02:06遺伝子の産物であるHLA-A*02:06分子へのペプチドの結合能の測定は、マウスのTAP(transporter associated with antigen processing)欠損細胞株であるRMASに、HLA-A*02:06遺伝子のcDNAを導入したRA2.6細胞(高知大学にて新たに作成した細胞株)を用いて行った。
(1)ペプチド刺激樹状細胞の調製
・Day0~9(樹状細胞の誘導)
HSP70に対する樹状細胞療法を受けた患者[0]からフェレーシスにより得られた末梢血単球のうち、培養フラスコに接着した細胞画分をAIM-CM培地(Gibco社製)中で10日間、37℃で培養した。培養期間中、培地に対し0日目及び3日目にIL-4を15μl、顆粒球単球コロニー刺激因子(GM-CSF)を30μlそれぞれ添加し、5日目にIL-4を15μl、GM-CSFを30μl、腫瘍壊死因子(TNF)-αを75μl添加した。
誘導した樹状細胞を新たにAIM-CM培地中に回収し、本発明のペプチド(配列番号1~11)が20μg/mlとなるよう添加した。その後、樹状細胞を含む培地を2時間37℃で培養した。ポジティブコントロール及びネガティブコントロールとして以下のペプチドを使用した。
HLA-A*24:02用ポジティブコントロール(EBV LMP2, 419-427:TYGPVFMCL(配列番号13))
HLA-A*24:02用ネガティブコントロール(HIV env gp160, 584-592:RYLRDQQLL(配列番号14))
HLA-A*02:01用ポジティブコントロール(Flu A MP, 58-66:GILGFVFTL(配列番号15))
HLA-A*02:01用ネガティブコントロール(HIV gap p17, 77-85:SLYNTVATL(配列番号16))
HLA-A*02:06用ポジティブコントロール(EBV LMP2 453-461:LTAGFLIFL(配列番号17))
HLA-A*02:06用ネガティブコントロール(HIV gap p24 341-349:ATLEEMMTA(配列番号18))
・Day0~9
上記ワクチンで2回以上治療された後の患者からフェレーシスにより得られた末梢血単球のうち、培養フラスコに接着しない浮遊細胞画分(リンパ球を含む)をAIM-CM培地(Gibco社製)中で10日間、37℃で培養した。培養期間中、培地に対し4日目及び6日目にそれぞれIL-2を40μl添加した。
CD8ネガティブセレクションキット(Miltenyi社製)を用いて培地からCD8T細胞を分離しセルカウントした。
上記(1)及び(2)で得られた樹状細胞とCD8T細胞を以下の条件にてAIM培地中で37℃で共培養した。
・CD8T細胞:5×105cells/well
・樹状細胞 :2×105cells/well
上記培地にIL-2 20U/ml を含んだAIM-CM培地0.4ml/wellを添加した。
・Day17
抗TFN-γモノクローナル抗体(MABTECH社製)をコートしたELISPOT用96穴プレート(Millipore社製)に、上記CD8T細胞を1穴あたり2×104cells/wellになるように加えた。各サンプルにつき、3ウェル以上使用した。各ウェルにはAIM-V(Gibco社製)を100μl添加した。ELISPOT用96穴プレートを37℃で培養した。
抗TFN-γ抗体を各ウェルに加え、さらにHRP酵素標識した2次抗体を反応させて、呈色反応により、IFN-γ産生細胞の数を測定した。代表的なELISPOTアッセイの結果として、HLA型が24:02/24:02の患者についてのものを図1に、02:01/24:02の患者についてのものを図2に、また、02:01/33:03の患者についてのものを図3に示す。各図において、3回ずつのアッセイ結果の平均値を表示する。
・Day17
T細胞と上記ペプチドでパルスした樹状細胞の共培養7日目の培養上清を、x1, x5, x25, x125の4段階に希釈し、Human IFN-γ ELISA MAX Deluxe Set (BioLegend社製)を用いて、測定限度内に収まる希釈段階を同定した。その後、同定した希釈段階にて、各サンプルにつき3回ずつ測定を行った。代表的なELISAアッセイの結果として、HLA型が24:02/26:01の患者、24:02/24:02の患者、11:01/24:02の患者、02:01/24:02の患者、02:01/33:03の患者、についてのものを順に図4~8に示す。
Claims (10)
- 配列番号1~11のいずれかで表されるアミノ酸配列における連続した8以上のアミノ酸残基を含み、且つ11以下のアミノ酸残基から成るペプチド。
- 前記アミノ酸配列中、1又は数個のアミノ酸が置換、挿入、欠失又は付加しており、且つ免疫原性を有する、請求項1に記載のペプチド。
- 前記アミノ酸配列中、第2位のアミノ酸がチロシン、フェニルアラニン、メチオニン、トリプトファン、バリン、ロイシン又はグルタミンで、そして/あるいはC末端のアミノ酸がフェニルアラニン、ロイシン、イソロイシン、トリプトファン、メチオニン又はバリンで置換されている、請求項2に記載のペプチド。
- 請求項1~3のいずれか1項に記載のペプチドを含む、癌の治療又は予防のための医薬組成物。
- ワクチンの形態である、請求項4に記載の医薬組成物。
- 前記ペプチドが1又は複数の型のHLA分子と結合することができる、請求項4又は5に記載の医薬組成物。
- 請求項1~3のいずれか1項に記載のペプチドを含む免疫誘導剤。
- 細胞傷害性T細胞を誘導するための、請求項7に記載の免疫誘導剤。
- 前記ペプチドが1又は複数の型のHLA分子と結合することができる、請求項7又は8に記載の免疫誘導剤。
- 請求項1~3のいずれか1項に記載のペプチドと抗原提示細胞とをin vitroで接触させる工程を含む、CTL誘導活性を有する抗原提示細胞の製造方法。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK16761783.6T DK3269733T3 (da) | 2015-03-09 | 2016-03-09 | Peptid afledt af gpc3, farmaceutisk sammensætning til behandling eller forebyggelse af cancer under anvendelse deraf, immunitetsinducer og fremgangsmåde til fremstilling af antigenpræsenterende celler |
US15/556,694 US10526388B2 (en) | 2015-03-09 | 2016-03-09 | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells |
AU2016230125A AU2016230125B2 (en) | 2015-03-09 | 2016-03-09 | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells |
EP16761783.6A EP3269733B1 (en) | 2015-03-09 | 2016-03-09 | Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells |
RU2017135038A RU2714117C2 (ru) | 2015-03-09 | 2016-03-09 | Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток |
CN201680014548.9A CN107428815B (zh) | 2015-03-09 | 2016-03-09 | 源于gpc3的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法 |
JP2017505374A JP6898225B2 (ja) | 2015-03-09 | 2016-03-09 | Gpc3由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
CA2979168A CA2979168A1 (en) | 2015-03-09 | 2016-03-09 | Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells |
BR112017018703-5A BR112017018703A2 (ja) | 2015-03-09 | 2016-03-09 | A medicine constituent for medical treatment of cancer using peptide of the GPC3 origin, and this, or prevention, an immunity inducer, and a manufacturing method of antigen presenting cells |
ES16761783T ES2805829T3 (es) | 2015-03-09 | 2016-03-09 | Péptido derivado de GPC3, composición farmacéutica para el tratamiento o la prevención de cáncer usando el mismo, inductor de inmunidad y método para producir células presentadoras de antígeno |
US16/185,734 US10590179B2 (en) | 2015-03-09 | 2018-11-09 | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells |
US16/782,544 US10875900B2 (en) | 2015-03-09 | 2020-02-05 | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-046463 | 2015-03-09 | ||
JP2015046463 | 2015-03-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/556,694 A-371-Of-International US10526388B2 (en) | 2015-03-09 | 2016-03-09 | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells |
US16/185,734 Division US10590179B2 (en) | 2015-03-09 | 2018-11-09 | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016143816A1 true WO2016143816A1 (ja) | 2016-09-15 |
Family
ID=56880605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/057356 WO2016143816A1 (ja) | 2015-03-09 | 2016-03-09 | Gpc3由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
Country Status (12)
Country | Link |
---|---|
US (3) | US10526388B2 (ja) |
EP (1) | EP3269733B1 (ja) |
JP (1) | JP6898225B2 (ja) |
CN (2) | CN113388021A (ja) |
AU (1) | AU2016230125B2 (ja) |
BR (1) | BR112017018703A2 (ja) |
CA (1) | CA2979168A1 (ja) |
DK (1) | DK3269733T3 (ja) |
ES (1) | ES2805829T3 (ja) |
RU (1) | RU2714117C2 (ja) |
TW (2) | TW202115102A (ja) |
WO (1) | WO2016143816A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018070069A1 (ja) * | 2016-10-11 | 2018-04-19 | サイトリミック株式会社 | 医薬 |
US10526388B2 (en) | 2015-03-09 | 2020-01-07 | Cytlimic Inc. | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells |
US10537626B2 (en) | 2014-10-07 | 2020-01-21 | Cytlimic Inc. | HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell |
US10842848B2 (en) | 2015-04-07 | 2020-11-24 | Cytlimic Inc. | Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein |
WO2023163094A1 (ja) * | 2022-02-25 | 2023-08-31 | 日本電気株式会社 | 成人t細胞白血病の治療又は予防のための医薬組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
CN113784974A (zh) * | 2019-05-02 | 2021-12-10 | L基础有限公司 | 新型寡肽和包含该寡肽作为活性成分的用于预防或治疗癌症的药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004018667A1 (ja) * | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ペプチド及びこれを含む医薬 |
WO2007018199A1 (ja) * | 2005-08-09 | 2007-02-15 | Kumamoto University | HLA-A2陽性者用glypican-3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬 |
US20130217122A1 (en) * | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196523A (en) | 1985-01-01 | 1993-03-23 | The University Of Southern California | Control of gene expression by glucose, calcium and temperature |
JPH08151396A (ja) | 1994-11-28 | 1996-06-11 | Teijin Ltd | Hla結合性オリゴペプチド及びそれを含有する免疫調節剤 |
EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
KR20040041575A (ko) | 2001-07-31 | 2004-05-17 | 칼 페터 쇠더스트룀 | 면역반응의 모듈화 조성물 및 모듈화 방법 |
AU2003300184B8 (en) | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
KR20080018201A (ko) | 2005-05-19 | 2008-02-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | E.coli 열 독소의 b서브유닛 및 항원 및애주번트를 포함하는 백신 조성물 |
US20100015101A1 (en) | 2006-03-28 | 2010-01-21 | Noriyuki Sato | Novel tumor antigen peptides |
RU2333767C2 (ru) | 2006-03-31 | 2008-09-20 | Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") | Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции |
US8557955B2 (en) | 2006-10-17 | 2013-10-15 | Oncotherapy Science, Inc. | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
US20100137221A1 (en) | 2007-02-27 | 2010-06-03 | University Utah Research Foundation | Peptides that interact with topoisomerase i and methods thereof |
JP2010538655A (ja) | 2007-09-12 | 2010-12-16 | アナフォア インコーポレイテッド | 自己免疫疾患についてのhsp70に基づく治療 |
KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
MX2012004095A (es) | 2009-10-06 | 2012-09-12 | Panacela Labs Inc | Uso del receptor tipo toll y agonista para tratar el cancer. |
EA201491481A1 (ru) | 2012-02-07 | 2014-11-28 | Ла Хойя Инститьют Фор Эллерджи Энд Иммьюнолоджи | Аллергены тимофеевки луговой и способы и применения для модулирования иммунного ответа |
WO2013143026A1 (en) | 2012-03-31 | 2013-10-03 | Abmart (Shanghai) Co., Ltd | Peptide and antibody libraries and uses thereof |
TWI693073B (zh) * | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
SG10201707135RA (en) | 2013-03-01 | 2017-10-30 | Astex Pharmaceuticals Inc | Drug combinations |
US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
AU2015329070B2 (en) | 2014-10-07 | 2018-11-22 | Nec Corporation | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell |
WO2016143816A1 (ja) | 2015-03-09 | 2016-09-15 | 日本電気株式会社 | Gpc3由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
RU2709015C2 (ru) | 2015-04-07 | 2019-12-13 | Ситлимик Инк. | Лекарственное средство |
AU2017342189B2 (en) * | 2016-10-11 | 2023-09-21 | Nec Corporation | Medicine |
-
2016
- 2016-03-09 WO PCT/JP2016/057356 patent/WO2016143816A1/ja active Application Filing
- 2016-03-09 EP EP16761783.6A patent/EP3269733B1/en active Active
- 2016-03-09 TW TW109142154A patent/TW202115102A/zh unknown
- 2016-03-09 DK DK16761783.6T patent/DK3269733T3/da active
- 2016-03-09 BR BR112017018703-5A patent/BR112017018703A2/ja not_active IP Right Cessation
- 2016-03-09 CA CA2979168A patent/CA2979168A1/en not_active Abandoned
- 2016-03-09 CN CN202110674116.3A patent/CN113388021A/zh active Pending
- 2016-03-09 ES ES16761783T patent/ES2805829T3/es active Active
- 2016-03-09 TW TW105107136A patent/TWI714558B/zh not_active IP Right Cessation
- 2016-03-09 JP JP2017505374A patent/JP6898225B2/ja active Active
- 2016-03-09 AU AU2016230125A patent/AU2016230125B2/en active Active
- 2016-03-09 CN CN201680014548.9A patent/CN107428815B/zh not_active Expired - Fee Related
- 2016-03-09 RU RU2017135038A patent/RU2714117C2/ru active
- 2016-03-09 US US15/556,694 patent/US10526388B2/en active Active
-
2018
- 2018-11-09 US US16/185,734 patent/US10590179B2/en active Active
-
2020
- 2020-02-05 US US16/782,544 patent/US10875900B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004018667A1 (ja) * | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ペプチド及びこれを含む医薬 |
WO2007018199A1 (ja) * | 2005-08-09 | 2007-02-15 | Kumamoto University | HLA-A2陽性者用glypican-3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬 |
US20130217122A1 (en) * | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
Non-Patent Citations (3)
Title |
---|
IWAMA, T. ET AL.: "Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide.", INT. J. ONCOL., vol. 42, no. 3, March 2013 (2013-03-01), pages 831 - 838, XP055309255, ISSN: 1019-6439 * |
KOMORI, H. ET AL.: "Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.", CLIN. CANCER RES., vol. 12, no. 9, 1 May 2006 (2006-05-01), pages 2689 - 2697, XP003020537, ISSN: 1078-0432 * |
NAKATSURA, T. ET AL.: "Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T- cell -mediated tumor rejection without autoimmune reactions in mice.", CLIN. CANCER RES., vol. 10, no. 24, 15 December 2004 (2004-12-15), pages 8630 - 8640, XP003016234, ISSN: 1078-0432 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10537626B2 (en) | 2014-10-07 | 2020-01-21 | Cytlimic Inc. | HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell |
US11304997B2 (en) | 2014-10-07 | 2022-04-19 | Cytlimic Inc. | HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell |
US10875900B2 (en) | 2015-03-09 | 2020-12-29 | Cytlimic Inc. | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells |
US10526388B2 (en) | 2015-03-09 | 2020-01-07 | Cytlimic Inc. | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells |
US10590179B2 (en) | 2015-03-09 | 2020-03-17 | Cytlimic Inc. | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells |
US10842848B2 (en) | 2015-04-07 | 2020-11-24 | Cytlimic Inc. | Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein |
US11491204B2 (en) | 2015-04-07 | 2022-11-08 | Cytlimic Inc. | Composition comprising poly I:C and LAG-3-IGG fusion protein |
WO2018070069A1 (ja) * | 2016-10-11 | 2018-04-19 | サイトリミック株式会社 | 医薬 |
RU2759728C2 (ru) * | 2016-10-11 | 2021-11-17 | Ситлимик Инк. | Лекарственное средство |
JP6998880B2 (ja) | 2016-10-11 | 2022-02-10 | サイトリミック株式会社 | 医薬 |
US11291718B2 (en) | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
JPWO2018070069A1 (ja) * | 2016-10-11 | 2019-09-26 | サイトリミック株式会社 | 医薬 |
US11759518B2 (en) | 2016-10-11 | 2023-09-19 | Nec Corporation | Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
WO2023163094A1 (ja) * | 2022-02-25 | 2023-08-31 | 日本電気株式会社 | 成人t細胞白血病の治療又は予防のための医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN107428815B (zh) | 2021-07-09 |
BR112017018703A2 (ja) | 2018-04-17 |
US10526388B2 (en) | 2020-01-07 |
CA2979168A1 (en) | 2016-09-15 |
CN113388021A (zh) | 2021-09-14 |
EP3269733A1 (en) | 2018-01-17 |
US20180105567A1 (en) | 2018-04-19 |
RU2017135038A3 (ja) | 2019-08-30 |
ES2805829T3 (es) | 2021-02-15 |
EP3269733B1 (en) | 2020-06-17 |
JP6898225B2 (ja) | 2021-07-07 |
RU2017135038A (ru) | 2019-04-08 |
DK3269733T3 (da) | 2020-07-27 |
US10875900B2 (en) | 2020-12-29 |
US20200157163A1 (en) | 2020-05-21 |
RU2714117C2 (ru) | 2020-02-11 |
JPWO2016143816A1 (ja) | 2018-03-01 |
AU2016230125A1 (en) | 2017-09-21 |
TWI714558B (zh) | 2021-01-01 |
AU2016230125B2 (en) | 2020-07-16 |
TW201639869A (zh) | 2016-11-16 |
US20190062389A1 (en) | 2019-02-28 |
US10590179B2 (en) | 2020-03-17 |
CN107428815A (zh) | 2017-12-01 |
TW202115102A (zh) | 2021-04-16 |
EP3269733A4 (en) | 2018-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6898225B2 (ja) | Gpc3由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 | |
US11304997B2 (en) | HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell | |
JP6481873B2 (ja) | Muc1由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 | |
WO2023163094A1 (ja) | 成人t細胞白血病の治療又は予防のための医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16761783 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017505374 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2979168 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017018703 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2016230125 Country of ref document: AU Date of ref document: 20160309 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15556694 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017135038 Country of ref document: RU |
|
REEP | Request for entry into the european phase |
Ref document number: 2016761783 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112017018703 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170831 |